Antiviral effect of double and triple drug combinations amongst HIV-infected adults: Lessons from the implementation of viral load-driven antiretroviral therapy

AIDS

Volumn 12, Issue 3, 1998, Pages 279-284

  Hogg, Robert S ^a,b   Rhone, Stephanie A ^a   Yip, Benita ^a   Sherlock, Chris ^a   Conway, Brian ^a   Schechter, Martin T ^a   O'Shaughnessy, Michael V ^a   Montaner, Julio S G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

Antiretroviral therapy; Didanosine; Lamivudine; Population based cohort; Protease inhibitors; Stavudine; Zalcitabine; Zidovudine

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CANADA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DIDANOSINE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MULTIVARIATE ANALYSIS; STAVUDINE; VIRAL LOAD; ZALCITABINE; ZIDOVUDINE;

EID: 0032510196     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199803000-00005     Document Type: Article

References (22)

1. Delta Coordinating Committee. Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine wilh zidovudine alone in HIV infected individuals. Lancet 1996, 348:283-291.
2. Hammer SM, Katzentein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV infected adults with CD4+ counts from 200 to 500 per cubic milliliter. N Engl J Med 1996, 335:1081-1090.
3. Collier AC, Coombs RW, Schoenfeld DA, et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996, 334:1011-1017.
4. Mathelz D, Bagnarelli D, Delruchis P, et al.: A triple combination of ritonavir + AZT + DDC as first line treatment of patients with AIDS. XI International Conference on AIDS. Vancouver, J uly 1996 [abstract MoB175].
5. 3. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 1B7].
6. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
7. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
8. CAESAR Coordinating Committee: Randomised trial of lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997, 349:1413-1421.
9. Montaner JSG, Hogg RS, O'Shaughnessy MV: Emerging international consensus for use of antiretroviral therapy. Lancet 1997, 349:10-42.
10. Gazzard BG, Movle GJ, Weber J, et al.: British HIV Association Guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997, 349:1086-1092.
11. Capenter CCJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. JAMA 1996, 276:146-454.
12. HIV/AIDS Clinical Trials and Treatments Advisory Committee: Antiretroviral therapy for HIV infection: principles of use. Standard of care guidelines. Darlingshurst: Australian National Council on AIDS and Related Diseases; October 1997.
13. Saag MS, Holodniv M, Kuritzkes DR, et al.: HIV viral load markers in clinical practice: recommendations of an International AIDS Society-USA Expert Panel.Nature Med 1996, 2:625-629.
14. BC Center for Excellence in HIV/AIDS: Therapeutic Guidelines for the Treatment of HIV/AIDS and Related Conditions, 1996. V Vancouver: BC Centre for Excellence in HIV/AIDS; 1996.
15. Hogg RS, O'Shaughnessy MV, Gataric N, et al.: AIDS death rates decline as a result of the availability of new antiretrovirals [letter] Lancet 1997, 349:1294.
16. World Health Organization: Acquired immune deficiency syndrome (AIDS): interim proposal for a WHO staging system for HIV infection and disease. WKLY Epidemol Rec 1990, 65:221-228.
17. Centers for Disease Control: Leads from the MMWR: revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. JAMA 1987, 258:1143-1154.
18. Neave HR, Worthington PL: Distribution-Free Tests, London: Routledge; 1998.
19. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human Immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
20. Raboud JM, Montaner JSG, Rae S, et al.: Predictors of duration of plasma viral load suppression. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September October 1997 [abstract A-14].
21. Carpenter CCJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV in 1997: updated recommendations of an international panel. JAMA 1997, 277:1962-1969.
22. Graham NH, Hoover DR, Park LP, et al.: Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Ann Intern Med 1996, 124:1031-1038.